Anzeige
Mehr »
Mittwoch, 18.03.2026 - Börsentäglich über 12.000 News
Geopolitik treibt Kurse: Wird dieses "unsichtbare" Metall zum nächsten Milliarden-Play?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
61 Leser
Artikel bewerten:
(0)

Philips unveils industry's first MRI guided user interface to simplify the imaging of growing patient population with MR Conditional implants at RSNA 2015

- ScanWise Implant[1] removes barriers and expands Philips' portfolio of diagnostic imaging solutions

- Technology supports healthcare professionals' first-time-right imaging for millions of patients with MR Conditional implants

AMSTERDAM, Nov. 30, 2015 /PRNewswire/ --Royal Philips (NYSE: PHG AEX: PHIA) today introduced ScanWise Implant, the industry's first MRI guided user interface and automatic scan parameter selection to help simplify the scanning of patients with MR Conditional implants, such as knee and hip replacements, spine implants and pacemakers, at the 2015 Radiological Society of North America Annual Meeting (RSNA). The new software helps users streamline exams and supports diagnostic confidence of this growing patient population. ScanWise Implant adds to Philips' suite of diagnostic imaging solutions designed to support healthcare professionals' first-time-right imaging, helping to improve hospital workflow, diagnostic confidence and, ultimately, patient experience.

Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/290893-NEW---151047-ScanWise-Implant-US_03.mp4

Logo - http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

Magnetic Resonance Imaging (MRI) is a modality of choice for diagnosing conditions such as neurological disorders, cancer, and muscle, joint and back pain. These conditions are most prevalent in older patient populations2, and the population with large joint replacements and implanted cardiac devices is expected to increase by about 70 percent over the next five years3.

However, implants can create a number of challenges with MRI exams. For example, it's difficult for clinicians to understand and scan within the safety limits defined by each implant manufacturer. These limits are not always clear or easy to implement on the MR scanner, causing patients with MR Conditional implants to often be denied MRI exams. In fact, every year 300,000 patients in the U.S. are denied access to MRIs because of a cardiac implantable electronic device4.

"We saw an opportunity to use our advanced digital health technology to help make MRIs more accessible to a patient population routinely denied access to this modality," said Robert Cascella, Executive Vice President and CEO, Philips Imaging. "At Philips, we strive to arm clinicians with innovative technology, so all patients can receive the most confident diagnosis and best treatment plans. By integrating patients, practitioners, and process with technology, we're helping radiology transform its care practice."

Increasing patient access to MRIs
Introducing MRI to a patient's diagnostic and treatment plan allows clinicians enhanced accuracy and improved workflow, and provides patients with access to better care. According to Harald Kugel, Ph.D., Department of Clinical Radiology, University of Munster, "The previous industry standard was: if patients had an implant, they couldn't be examined with MR. However, patients deserve the best imaging modality available and shouldn't be excluded from a modality, because risks aren't truly known and documented. It's a milestone achievement that Philips developed an answer for patients with conditional implants to have access to MRIs."

"From a technologist's perspective, we're excited about the prospect of shortening exam times and broadening the diagnostic modalities available for those patients with MR Conditional implants," said Scott Hipko, Chief MRI Research Technologist, The University of Vermont, College of Medicine. "Philips understands the needs of radiologists and brings the expertise needed to create a smart solution to help guide operators to meet the specific criteria for each implant."

ScanWise Implant is the newest addition to Philips' advanced diagnostic imaging solutions designed to support first-time-right imaging. Other products within this portfolio include:

  • Ingenia 1.5T S which is designed for first-time-right imaging and increased patient comfort for a faster workflow5;
  • mDIXON XD which provides fast, sharp and fat-free imaging for all anatomies, increasing the diagnostic information by providing two contrasts in a single scan; and
  • Philips' MR in-bore experience which helps to improve the patient experience and utilizes AutoVoice and ComforTone to turn the patient exam into an event.

The ScanWise Implant, along with Philips' diagnostic imaging solutions, is featured in booth #6736 at RSNA through Dec. 4 in Chicago, Ill. Follow @PhilipsLiveFrom or visit www.philips.com/rsna for more information on Philips' presence at RSNA15.

For further information, please contact:
Kathy O'Reilly
Philips Group Communications
Tel: +1 978-221-8919
Email: Kathy.Oreilly@philips.com
Twitter: @kathyoreilly

Adrienne Smith
Philips Diagnostic Imaging
Tel.: + 1 781-277-1170
E-mail: Adrienne.Smith@philips.com
Twitter: @AdrienneSmith12

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 106,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

1 510(k) pending. Not available in the U.S.
2 National Cancer Institute April 2009. US estimated complete prevalence (including counts) by age on 1/1/2006; Arthritis Rheum. May 1998; 41 (5):778-799; American Heart Association. Heart Disease and Stroke Statistics - 2010 Update: Learn and Live. Prevalence of stroke by age and sex (NHANES: 2003-2006).
3 Large Joint Reconstructive Implants US_ 2015, MRG Spine US 2015, MRG- Cardiac rhythm management rhythm management device| global | 2014 | Market Analysis.
4 Cogn Int Conf Adv Cogn Technol Appl. 2014; 2014: 235-238.
5 Increased patient comfort with the patient in-bore solution compared to without, faster workflow compared to Philips Achieva.

© 2015 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.